日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial

VERTIS CV试验中,通过不良事件报告记录的2型糖尿病合并动脉粥样硬化性心血管疾病患者的心力衰竭结局:

Pandey, Ambarish; Kolkailah, Ahmed A; McGuire, Darren K; Frederich, Robert C; Cater, Nilo B; Cosentino, Francesco; Pratley, Richard E; Dagogo-Jack, Samuel; Cherney, David Z I; Wynant, Willy; Gantz, Ira; Mancuso, James P; Masiukiewicz, Urszula; Cannon, Christopher P

Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial

VERTIS CV试验中,基线BMI与长期体重减轻和心肾结局的关系

Cosentino, Francesco; Dagogo-Jack, Samuel; Frederich, Robert; Cannon, Christopher P; Cherney, David Z I; Mancuso, James P; Wynant, Willy; Xing, Aiwen; Gantz, Ira; Cater, Nilo B; Pratley, Richard E

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

根据基线使用肾素-血管紧张素-醛固酮系统抑制剂或利尿剂(包括盐皮质激素受体拮抗剂)的情况,对接受 Ertugliflozin 治疗的患者进行心血管和肾脏结局分析:来自 VERTIS CV 试验的分析

Cherney, David Z I; Frederich, Robert; Pratley, Richard E; Cosentino, Francesco; Dagogo-Jack, Samuel; Pong, Annpey; Gantz, Ira; Cater, Nilo B; Mancuso, James P; Masiukiewicz, Urszula; Cannon, Christopher P

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

Ertugliflozin 与心力衰竭住院治疗的关系(涵盖试验前射血分数范围):VERTIS CV 试验的事后分析

Pandey, Ambarish; Kolkailah, Ahmed A; Cosentino, Francesco; Cannon, Christopher P; Frederich, Robert C; Cherney, David Z I; Dagogo-Jack, Samuel; Pratley, Richard E; Cater, Nilo B; Gantz, Ira; Mancuso, James P; McGuire, Darren K

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity

艾格列净联合二甲双胍治疗的疗效和安全性:一项来自亚洲的2型糖尿病合并超重或肥胖人群的汇总研究

Ji, Linong; Liu, Jie; Xu, Zhi Jin; Wei, Zhiqi; Zhang, Ruya; Malkani, Seema; Cater, Nilo B; Frederich, Robert

External Stimuli on Neural Networks: Analytical and Numerical Approaches

外部刺激对神经网络的影响:解析方法和数值方法

Curado, Evaldo M F; Melgar, Nilo B; Nobre, Fernando D

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

埃格列净对 2 型糖尿病合并已确诊动脉粥样硬化性心血管疾病患者心力衰竭相关事件的疗效:VERTIS CV 试验结果

Cosentino, Francesco; Cannon, Christopher P; Cherney, David Z I; Masiukiewicz, Urszula; Pratley, Richard; Dagogo-Jack, Sam; Frederich, Robert; Charbonnel, Bernard; Mancuso, James; Shih, Weichung J; Terra, Steven G; Cater, Nilo B; Gantz, Ira; McGuire, Darren K

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

艾格列净在东亚/东南亚2型糖尿病患者中的疗效和安全性

Liu, Jie; Patel, Shrita; Cater, Nilo B; Wu, Larry; Huyck, Susan; Terra, Steven G; Hickman, Anne; Darekar, Amanda; Pong, Annpey; Gantz, Ira

Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study

非诺贝特联合低剂量烟酸治疗2型糖尿病:一项开放标签、交叉研究

Vega, Gloria Lena; Vajja, Monohar; Palacio, Natalia; Caterp, Nilo B; Grundy, Scott M